|
Press Releases |
|
 |
|
Wednesday, April 9, 2025 |
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
中國抗體製藥有限公司SM17治療特應性皮炎1b期概念驗證臨床試驗取得突破性結果 |
中國抗體製藥有限公司(「中國抗體」或「本公司」;股份代號:3681)宣佈,其SM17針對中重度特應性皮炎(AD)的創新療法已完成1b期臨床研究,並獲得突破性頂線數據結果。 more info >> |
|
中国抗体制药有限公司SM17治疗特应性皮炎1b期概念验证临床试验取得突破性结果 |
中国抗体制药有限公司(“中国抗体”或“本公司”;股份代号:3681)宣布,其SM17针对中重度特应性皮炎(AD)的创新疗法已完成1b期临床研究,并获得突破性顶线数据结果。 more info >> |
|
Tuesday, April 16, 2024 |
|
中国抗体SM17治疗特应性皮炎(AD)之临床前结果刊登于国际科学期刊《Allergy》 |
more info >> |
|
中國抗體SM17治療特應性皮炎(AD)之臨床前結果刊登於國際科學期刊《Allergy》 |
more info >> |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
中国抗体SM17新药研究申请再获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗特应性皮炎(“AD”)的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”) more info >> |
|
中國抗體SM17新藥研究申請再獲國家藥監局批准 |
專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,本公司所提交之治療特應性皮炎(「AD」)的同類首創(First-in-Class)治療產品SM17的新藥研究申請(「新藥研究申請」) more info >> |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗哮喘的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”)于2023年8月11日获中国国家药品监督管理局(“国家药监局”)批准。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Galaxy Payroll Group Limited Announces Execution of PIPE Financing Agreements
Jul 15, 2025 05:30 HKT/SGT
|
|
|
Kingnet Acquired Type 4 and Type 9 Licenses: Continuously Broadening Business Boundaries and Advancing Global Expansion Layout
Jul 14, 2025 23:47 HKT/SGT
|
|
|
愷英網絡獲得4號及9號牌照:持續拓寬業務邊界 全球化佈局更進一步
Jul 14, 2025 23:46 HKT/SGT
|
|
|
Graphene Aluminium Ion Battery Patent Granted and GMG and The University of Queensland Enter into New Collaboration Agreement
Jul 14, 2025 20:09 HKT/SGT
|
|
|
BlockBits Launches a Futures Trading Service, Offering Traders a Wide Range of Advanced Tools
Jul 14, 2025 20:00: JST
|
|
|
BlockBits Launches a Futures Trading Service, Offering Traders a Wide Range of Advanced Tools
Jul 14, 2025 20:00 HKT/SGT
|
|
|
XDS Datacentres signs 15-year deal to host 10MW of AI workloads in Saudi's Desert Dragons facilities
Jul 14, 2025 18:00: JST
|
|
|
XDS Datacentres signs 15-year deal to host 10MW of AI workloads in Saudi's Desert Dragons facilities
Jul 14, 2025 17:00 HKT/SGT
|
|
|
恺英网络获得4号及9号牌照:持续拓宽业务边界 全球化布局更进一步
Jul 14, 2025 16:01 HKT/SGT
|
|
|
Buy International Homes at the Global Property Expo, Singapore
Jul 14, 2025 14:48 HKT/SGT
|
|
|
富士通、特化型AIエージェントでグローバルサプライチェーンを最適化するソリューションが、ビジネスを変革する先進事例として選定
Jul 14, 2025 11:00: JST
|
|
|
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
|
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
|
|
|
エーザイ、痛風治療剤「URECE」(一般名:ドチヌラド)を中国において新発売
Jul 14, 2025 09:00: JST
|
|
|
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
|
|
|
|
More News >> |
|
|
|
|
|